Verve Therapeutics
NEWS
Monday, Verve Therapeutics revealed that the FDA has officially requested several buckets of additional safety information to lift the hold on its lead candidate, VERVE-101.
Verve Therapeutics’ base editing program has been forced into a detour after the FDA placed a hold on its investigational new drug application. Beam has also posted its own regulatory update.
Vertex and Verve announced they had entered an exclusive four-year research partnership to discover and nurture a gene editing therapy for yet-undisclosed liver disease.
Verve Therapeutics dosed its first patient with VERVE-101, a one-time treatment that aims to permanently lower low-density lipoprotein (LDL) cholesterol in patients and prevent heart disease.
When Sekar Kathiresan’s brother unexpectedly died from a heart attack, he changed the course of his life to found a company with a novel medicine that may prevent them.
The year kicked off with a bang as multiple companies raced to a public listing.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Life sciences advances continue to be an exciting opportunity for investors. Here’s a glance at the companies attracting fresh funding the past week.
Biotech companies are dominating Nasdaq’s IPO scheduled this week. Here’s who is making their big public debut.
JOBS
IN THE PRESS